Shares of Taysha Gene Therapies, Inc. (TSHA) are soaring 5.47% in pre-market trading on Friday, buoyed by positive analyst ratings. The gene therapy company has caught the attention of Wall Street, with multiple firms reiterating their bullish stance on the stock.

Citizens JMP analyst Silvan Tuerkcan maintained a Buy rating on Taysha Gene Therapies, setting a price target of $5.00. This vote of confidence from a respected analyst likely contributed to the positive sentiment surrounding the stock. Additionally, Canaccord Genuity also maintained its Buy rating on TSHA, further reinforcing the optimistic outlook for the company.

These favorable analyst actions suggest that Wall Street sees potential in Taysha Gene Therapies' pipeline and business prospects. As investors often look to analyst ratings for guidance, these maintained Buy ratings could be driving increased interest in TSHA shares, leading to the significant pre-market surge. However, investors should always conduct their own research and consider their risk tolerance before making investment decisions based on analyst recommendations.